11th RWE, Market Access, Pricing & Reimbursement 2024 Americas
Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines
Day 1 - Monday 9th September 2024
TRENDS & STRATEGIES
- Trends that will continue to impact, Market Access, Pricing and Reimbursement in healthcare
- Unlocking data from early access
- Effective communications with internal and external stakeholders
- Embracing the digital vision
- Future trends and developments in the healthcare distribution
- Keeping on top of pricing and market access trends
- Identify a clinical or economic advantage and generate the appropriate clinical and health
economic evidence to support a strong value proposition - The importance of Patient-Reported Outcomes
- Unlocking data from early access
- Effective communications with internal and external stakeholders
- Embracing the digital vision
- Understanding the intricate regulatory landscape
- Navigating complex requirements to achieve and maintain market access in the US and around the world
- Practical approaches and strategic planning
- Best practices
- Benefits of understanding differences across stakeholders
- Multiple stakeholder approach to planning and delivering evidence is required
A dedicated strategy to meet their specific evidence needs
Determine whether a multiple stakeholder approach is justified.
- New landscape for risk-sharing agreements among manufacturer, payer and patients
- Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
- What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?
- Addressing the factors that made the launch environment more challenging
- Capabilities needed for an effective drug launch
- How to best leverage outsourced partners to achieve success.
- Best practices to achieve successful commercialisation.
REAL-WORLD EVIDENCE
- Recent advances in digital and advanced analytics for RWE generation
- What role can it play across the pharma value chain?
- What are the important aspects involved in utilising RWE to support product effectiveness?
- How can this be used to advance reimbursement model?
- Major factors contributing to the pharmaceutical industry’s excitement about RWE
- Addressing the challenges of collecting and consolidating RWD data that can be put to good use.
- Important role of RWE clinical trials
- Real-world data and evidence as a more integral part of the drug development process.
Jason Noto, Senior Vice President, US Market Access, AVEO Oncology
- How is RWD and RWE bringing innovation to patients and gaining approval
- Importance of RWD in transforming clinical research and clinical trial design
- Experiences to date and identify practical and technological considerations to further implement real-world clinical research
- The use of RWD early in the process to boost trial diversity and inclusion
- Challenge in setting diversity goals early in clinical trial planning
- Development of a diversity plan to ensure adequate representation of racial and ethnic
subgroups in clinical trials - Utilizing RWE in the post-marketing setting to complement clinical trial findings and support post-marketing requirements or commitments for safety and efficacy data in a diverse patient population
- Why is RWE increasingly being recognised and acknowledged as an evolution in product research and development.
- How does RWE help regulators, pharmaceutical companies and clinicians better identify trends and patterns in patient outcomes
- Understanding the risks & opportunities to both payer and industry
- How does real-world evidence help ensure market access?
- It’s use in supporting a robust post market surveillance and accelerating products to market